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OLIGONUCLEOTIDE DELIVERY SYSTEMS 
FOR CAMPTOTHECINS 
This is a National Stage Application under 35 U.S.C. 
§371 of International Application No. PCT/US98/20941, 
?led on Oct. 14, 1998. 
This invention Was made With Government support 
under NIH grant NIH CA: 63653. The Government may 
have certain rights in this invention. 
TECHNICAL FIELD 
The present invention relates generally to camptothecin 
anticancer drugs and the use of oligonucleotides to bind 
selectively the lactone forms of camptothecins, thereby 
conserving the agents in their biologically active lactone 
forms. 
BACKGROUND OF THE INVENTION 
Camptothecin, a plant alkaloid isolated from trees indig 
enous to China, and analogues thereof such as 
9-aminocamptothecin, 9-nitrocamptothecin, 
10-hydroxycamptothecin, 10,11 
methylenedioxycamptothecin, 9-nitro- 10,1 1 - 
methylenedioxycamptothecin, 9-chloro-10,11 - 
methylenedioxycamptothecin, 9-amino-10,11 
methylenedioxycamptothecin, 7-ethyl- 10 
hydroxycamptothecin (SN-38), topotecan, DX-8951, 
GG211, 7-trimethylsilylmethylcamptothecin, and other ana 
logues (collectively referred to herein as camptothecin 
drugs) are presently under study WorldWide in research 
laboratories and cancer clinics. In lab tests and in clinical 
trials, these camptothecin drugs have aroused considerable 
interest as a result of their ability to halt the groWth of a Wide 
range of human tumors. For example, these drugs exhibit 
unprecedented high levels of antitumor activities against 
human colon cancer [Giovanella, et al. Science 246: 
1046—1048 (Wash. DC.) (1989)]. Camptothecin has also 
been shoWn to be effective against other experimental cancer 
types such as lung, breast, and malignant melanoma. 
Camptothecin is thought to inhibit the proliferation of 
cancer cells by interfering With the breakage/reunion reac 
tion of the enZyme topoisomerase I, a nuclear enZyme 
implicated in DNA replication and RNA transcription. A 
camptothecin drug stabiliZes and forms a reversible enZyme 
camptothecin-DNA ternary complex, designated the cleav 
age complex. The formation of the cleavable complex 
speci?cally prevents the reunion step of the breakage/union 
cycle of the topoisomerase reaction. 
HoWever, the clinical use of the camptothecin drugs is 
limited by their chemical properties. First, the camptothecin 
drugs are insoluble in Water Which hinders the delivery of 
the drug to the cancer cells. Second, the camptothecin drugs 
are extremely susceptible to hydrolysis; in an aqueous 
environment such as blood plasma, the half life is about 16 
to 20 minutes and active lactone concentrations can fall to 
almost negligible levels depending upon the analogue. The 
camptothecin drugs each contain a substituted quinoline 
nucleus (rings A—C) and, at the opposite end an ot-hydroxy 
lactone ring Which is very unstable in aqueous environ 
ments. In blood plasma the ring is quickly opened to create 
the carboxylate form of the drug, Which is poorly accumu 
lated by cancer cells. Once internaliZed by the cancer cells, 
the carboxylate form exhibits no activity against its molecu 
lar target, topoisomerase I. Thus, the hydrolyZed product is 
ineffective at treating cancer. Moreover, the hydrolyZed 
product appears to be more toxic to healthy tissue than the 
camptothecin drugs. 
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Numerous attempts have, of course, been made to address 
these problems and shortcomings. To date, one of the most 
successful Ways for maintaining camptothecin drugs in the 
antitumor-active lactone form is by stabiliZation of the drug 
in macromolecular lipid or surfactant assemblies such as 
liposomes or micelles, The liposomal or micellular stabili 
Zation of camptothecins is described in detail in US. Pat. 
Nos. 5,552,156 and 5,736,156 both to Burke. Speci?cally, 
the lactone ring of the camptothecin drugs is stabiliZed in the 
membrane of the vesicles. Typically, the camptothecin drugs 
bind the lipid bilayer membrane of the liposome and the 
surfactant monolayer membrane of the micelles. The 
liposome-bound or micelle-bound drug is protected from 
hydrolysis, thus preserving the antitumor activity of the 
drug. 
The liposome is comprised of lipids such as, for example, 
phospholipids or cholesterol. For the camptothecin drugs 
Which have a lower affinity for the liposome membrane and 
thus disassociate from the liposomal membrane to reside in 
the interior of liposome, the pH of the internal environment 
of the liposome is reduced thereby preventing hydrolysis of 
the camptothecin drug. Camptothecin drugs are also stabi 
liZed by association With micelles comprised of surfactants 
such as sodium dodecylsulfate (SDS), octylphenolpolyoxy 
ethylene glycol and sorbitan mono-oleate. 
Recently the effectiveness of liposomal topotecan formu 
lations Were evaluated in animal models. Although topote 
can exhibits good clinical activity against a variety of tumor 
types, it undergoes rapid hydrolysis in vivo from the active, 
lactone species to the inactive carboxylate. This inactivation, 
coupled With cell-cycle-speci?c behavior and fairly rapid 
elimination, results in highly schedule-dependent clinical 
activity. Liposomal carriers accumulate selectively at tumor 
sites and can potentially act as sustained release systems 
maintaining therapeutic drug levels over a prolonged period. 
In the case of topotecan, such carriers might also protect the 
drug in its lactone form until released. A procedure Whereby 
topotecan could be efficiently encapsulated Within lipid 
based carriers employing an ion gradient loading procedure 
and delivered to tumors has been developed (Madden et al., 
1998). In contrast to earlier studies on liposomal delivery in 
Which camptothecins Were inserted predominantly into the 
lipid bilayer, the current technique entraps topotecan in the 
aqueous core of the carrier. Drug uptake Was rapid 
(approximately 60 min. at 60° C.) and high encapsulation 
ef?ciencies (>95%) Were readily achieved at relatively high 
drugzlipid ratios (0.1:1 mole ratio). Plasma elimination rates 
Were compared for free topotecan and encapsulated drug 
(liposomal topotecan) in mice. FolloWing a bolus intrave 
nous injection (lateral tail vein) at 10 mg/kg, plasma level 
Were folloWed for up to 24 hours. Plasma levels of topotecan 
given in the liposomal formulation Were approximately tWo 
orders of magnitude higher than for free drug over this 
timecourse. Further, by employing carriers With an acidic 
interior the entrapped topotecan Was protected as the lactone 
species (85% lactone at 24 hours). Antitumor ef?cacy Was 
compared for free and liposomal topotecan in the murine 
L1210 model (i.p. tumor inoculation/i.v. treatment) using 
either a single bolus injection on day 1 (10 or 20 mg/kg), or 
bolus injections on days 1, 5, 9 (4 or 8 mg/kg). In all 
treatment schedules liposomal topotecan exhibited much 
greater antitumor activity than did free drug. 
While the liposomal and micellar stabiliZation of camp 
tothecin drugs described in US. Pat. Nos. 5,552,156 and 
5,736,176 to Burke address and effectively overcome the 
instability and insolubility problems of camptothecin drugs 
administered in their free form, further improvements lead 
US 6,897,200 B1 
3 
ing to more efficient, diversi?ed and effective administration 
and treatment of tumors and various cancer types are still 
possible and are actively being sought. 
ToWard that end, We have developed the present inven 
tion. Speci?cally, We have found that direct noncovalent 
binding interactions of camptothecin drugs With oligonucle 
otides conserve the active forms of the drugs (i.e. the active 
lactone forms of camptothecin drugs are found to be stable 
When complexed With oligonucleotides). The oligonucle 
otides include single-stranded DNA, double-stranded DNA, 
antisense DNA, RNA, and catalytic RNA. The invention 
describes macromolecular assemblies Which include both 
viral or non-viral oligonucleotide vectors. The viral gene 
delivery systems include retroviruses, adenoviruses, adeno 
associated viruses, Herpes viruses, Vaccinia viruses, and 
other virus particles. The non-viral delivery systems include 
transfection vehicles, naked DNA for injection, gene gun 
particles, liposomes including cationic liposomes, 
virosomes, receptor-mediated delivery vehicles, and biode 
gradable and non-biodegradable polymer matrixes. The 
macromolecular assemblies can consist of the folloWing 
materials: biodegradable and non-biodegradable polymers, 
lipids, carbohydrates, proteins and biologically relevant 
molecules Which facilitate the delivery, accumulation and 
processing of the oligonucleotides and drugs to target tissues 
Within the human body. Each of the above oligonucleotide 
delivery vectors contain oligonucleotides Which act to sta 
biliZe the lactone forms of camptothecin drugs. The oligo 
nucleotide contained Within the vectors can serve as a 
stabiliZing matrix for the drug and the stabiliZation can be 
effective over a Wide pH range, the vectors also provide a 
means for the controlled, targeted and stable delivery of 
camptothecin drug to target tissue. In addition to stabiliZing 
camptothecin, the oligonucleotides carried in the vectors 
serve an additional role in exerting gene therapy or phar 
macological effects in general Which can be envisioned to 
augment the effects of camptothecins on the host target 
tissue and the patient receiving the therapy. The combination 
of stable camptothecin drug delivery and gene therapy can 
have potentially unique and desirable consequences on 
inhibiting the spread of cancer and other disease states in 
humans and animals. 
SUMMARY OF THE INVENTION 
Accordingly, it is a primary object of the present invention 
to provide stable, Water soluble, highly pharmacologically 
active camptothecin drugs overcoming the above described 
limitations and disadvantages of the prior art including the 
instability and insolubility problems of camptothecin drugs 
administered in free form. 
Still another object of the present invention is to provide 
camptothecin drugs formed in complex With an oligonucle 
otide including DNA and RNA Wherein the formation of the 
complex results in binding interactions betWeen the active 
lactone form of the drug and the oligonucleotide. 
The prior art concerning camptothecin interactions With 
DNA indicated that there Was only very limited direct 
experimental evidence that camptothecin and its analogs/ 
derivatives bind to oligonucleotides such as DNA in the 
absence of the t+opoisomerase I protein. Earlier Work sug 
gests that camptothecin derivatives bind to neither isolated 
DNA structures nor isolated topoisomerase I; the researchers 
indicated that the drug only binds to the DNA 
topoisomerase 1 complex (HertZberg et al., J. Biol. Chem. 
265: 19287—19295 (1990)). Other studies have suggested 
that camptothecin drugs may Weakly interact With intact 
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dsDNA, but no effect on the active lactone drug concentra 
tions Were reported (Fukada et al., Biochemical Pharmacol 
ogy 34: 1225—1230 (1985); Leteurtre et al., Biochemistry 32: 
8955—8963 (1993)). Until We completed our studies it Was 
not knoWn that camptothecins can bind to DNA and these 
interactions act to conserve the active lactone forms of these 
medications (Yang et al. J. Am. Chem. Soc. 120: 2979—2980 
(1998). 
The present invention relates generally to camptothecin 
anticancer drugs and the use of oligonucleotides to bind 
selectively the lactone forms of camptothecin drugs. The 
binding interactions act to conserve the agents in their 
biologically-active lactone forms. Direct noncovalent bind 
ing interactions of a camptothecin drug of SN-38 lactone 
With oligonucleotide is described here. The interactions are 
found to conserve the active forms of the drugs (i.e. the 
active lactone forms of camptothecins are found to be stable 
When complexed With oligonucleotides). 
The oligonucleotides include single-stranded DNA, 
double-stranded DNA, antisense DNA, RNA, and catalytic 
RNA, among others. This invention describes macromo 
lecular assemblies Which include both viral or non-viral 
oligonucleotide vectors. The viral gene delivery systems 
include retroviruses, adenoviruses, adeno-associated 
viruses, Herpes viruses, Vaccinia viruses, and other virus 
particles. The non-viral delivery systems include transfec 
tion vehicles, naked DNA for injection, gene gun particles, 
liposomes including cationic liposomes, virosomes, 
receptor-mediated delivery vehicles, and biodegradable and 
non-biodegradable polymer matrixes. 
Camptothecin drugs complexed in a reversible manner to 
oligonucleotides (for both Water-soluble oligonucleotide 
camptothecin drug complexes or oligonucleotide 
camptothecin drug complexes contained in particles such as 
virus particles) can gain entry into cancer cells. Because the 
drugs are reversibly complexed With the oligonucleotides, 
the drugs can dissociate from the oligonucleotides and be 
able to exert their effect on the topoisomerase I target Within 
the cancer cell. In the special case Where covalent interac 
tions betWeen camptothecin drug and oligonucleotide put 
the drug in closer proximity to the macromolecule, such that 
the probability of lactone binding and stabiliZation is greater, 
cellular metabolism Will be necessary to release the drug 
from the oligonucleotide. 
The oligonucleotide-camptothecin drug complexes can be 
further incorporated into macromolecular assemblies for 
optimiZation of controlled drug release and delivery char 
acteristics. The oligonucleotide-DNA complexes can consist 
of the folloWing materials: biodegradable and non 
biodegradable polymers, lipids, carbohydrates, proteins and 
biologically relevant molecules Which facilitate the delivery, 
accumulation and processing of the oligonucleotides and 
drugs to target tissues Within the human body. Each of the 
above oligonucleotide delivery vectors containing oligo 
nucleotides can act to stabiliZe the lactone forms of camp 
tothecin drugs. The oligonucleotide contained Within the 
vectors can serve as a stabiliZing matrix for the drug and the 
stabiliZation can be effective over a Wide pH range; the 
vectors also provide a means for the controlled, targeted and 
stable delivery of camptothecin drug to target tissue. In 
addition to stabiliZing camptothecin, the oligonucleotides 
carried in the vectors serve an additional role in exerting 
gene therapy or pharmacological effects in general Which 
can be envisioned to augment the effects of camptothecins 
on the host target tissue and the patient receiving the therapy. 
The combination of stable camptothecin drug delivery and 
gene therapy can have potentially unique and desirable 
US 6,897,200 B1 
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consequences on inhibiting the spread of cancer and other 
disease states in humans and animals. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying drawing incorporated in and forming 
a part of the speci?cation, illustrates several aspects of the 
present invention and together With the description serves to 
explain the principles of the invention. In the draWing: 
FIG. 1 is a summary of the structures of several clinically 
relevant camptothecins including camptothecin (CPT), CPT 
11, SN-38, and topotecan (TPT). Also shoWn at the bottom 
of the ?gure are the D and E rings of the drugs, With the 
depiction shoWing the pH-dependent conversion betWeen 
the lactone and carboxylate forms of the drug. At physi 
ological pH the carboxylate form of the drug is by far the 
predominant form of the drug. 
FIG. 2 represents a kinetic evaluation of the rate of 
lactone ring opening for topotecan (left panel) and CPT-11 
(right panel) in the presence and absence of duplex DNA 
oligonucleotides ((dG-dC)5 or (dA-dT)15). Data for drug in 
the absence of DNA (triangles), drug in the presence of 
(dG-dC)15 (solid circles) or (dA-dT)15 (open circles) are 
shoWn. All experiments Were conducted in phosphate buff 
ered saline (PBS) (pH 7.40:0.05) at room temperature. Drug 
and DNA concentrations of 10 pM and ~30 mM base, 
respectively, Were employed. Each pro?le represents the 
average of at least three independent kinetic runs With the 
same sampling schedules. The standard deviation of each 
point Was typically 5% or less. Kinetic parameters for the 
various samples are summariZed in Table 1. 
FIG. 3 represents a kinetic evaluation of the rate of 
lactone ring opening for topotecan and CPT-11 in the 
presence of various concentrations of duplex DNA oligo 
nucleotides (GC15 and AT15) and single-strand DNA (dT)3O. 
All experiments Were conducted in PBS (pH 7.40:0.05) at 
room temperature. Drug concentrations of 10 pM and DNA 
concentrations of 30 mM base for dsDNA and 33 mM base 
for ssDNA (dT)3O Were employed. Each pro?le represents 
the average of at least three independent kinetic runs With 
the same sampling schedules. The standard deviation for 
each point is typically 5% or less. Standard deviations in the 
kinetic results When using different DNA synthetic batches 
can range up to 10%. Kinetic parameters for the various 
samples are summariZed in Table 1. 
FIG. 4 depicts the stability of topotecan in the presence of 
various concentrations of RNA at 22° C. In these 
experiments, topotecan (at a ?nal concentration of 1 pM) 
Was incubated in PBS, pH 7.4 in the presence of various 
concentrations of RNA (total RNA from yeast) for 30 min at 
22° C. and analyZed for the fraction of lactone present by 
reversed-phase HPLC. The ?gure indicates that the presence 
of RNAprovides a means of enhancing the amount of active 
lactone form of the drug. As an example, in the presence of 
7.5 mg/ml of RNA there exists a 10% greater amount of the 
lactone form than found in the absence of RNA. 
FIG. 5. Stability of topotecan in the presence of various 
concentrations of RNA at 37° C. Topotecan (1 pM ?nal 
concentration) Was incubated in PBS, pH 7.4 in the presence 
of various concentrations of RNA (total RNA from yeast) for 
30 min at 37° C. and analyZed for the fraction of lactone 
present by reversed-phase HPLC. At a RNA concentration 
of 7.5 mg/ml, 12% more of the lactone form of topotecan is 
present. 
FIG. 6 represents a comparison of the stability of topo 
tecan in the presence and absence of RNA at 22° C. 
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Topotecan (1 pM ?nal concentration) Was incubated in PBS, 
pH 7.4 either alone (?lled circles) or in the presence of 10 
mg/ml of RNA (open circles) at 22° C. and analyZed for the 
fraction of lactone present at different times by reversed 
phase HPLC. The ?gure indicates that in the presence of 10 
mg/ml of RNA, 25% more of the lactone form of topotecan 
is present after 3 hrs. 
FIG. 7 represents a comparison of the stability of topo 
tecan in the presence and absence of RNA at 37° C. 
Topotecan (1 pM ?nal concentration) Was incubated in PBS, 
pH 7.4 either in the absence (?lled circles) or in the presence 
of 10 mg/ml of RNA (open circles) at 37° C. and analyZed 
for the fraction of lactone present at different times by 
reversed-phase HPLC. The ?gure indicates that in the pres 
ence of 10 mg/ml of RNA, 15% more of the lactone form of 
topotecan is present after 3 hrs. 
FIG. 8 depicts the marked shifting of the ?uorescence 
emission spectra of SN-38 lactone (1 MM ?nal 
concentration) in the presence of double-stranded DNA 
(dsDNA). SN38 contains a 10-hydroxy-nctionality Which 
results in the molecule having a ?uorescence emission 
Which is highly sensitive to the presence of Water in the 
surrounding microenvironment. The inset of the ?gure 
shoWs the dramatic shifting of the ?uorescence of the 
molecule When Water is excluded from the microclimate of 
the ?uorophore. Note hoW the agent ?uoresces in the 410 nm 
to 460 nm region When Water is not present, but ?uoresces 
at 520 to 530 nm When Water is present. Note hoW the 
?uorescence of SN38 lactone shifts markedly to loWer 
Wavelength upon interacting With double-stranded DNA, 
clearly indicating that the agent is capable of directly 
interacting With the DNA. These data indicate that by 
interacting With DNA, the ?uorophore can relocate to dif 
ferent microenvironment With markedly reduced Water con 
tent. The ?uorophore Was directly added to the DNA solu 
tion and the spectra recorded immediately (Within 2 min.) 
prior to any signi?cant conversion of the agent to carboxy 
late form. 
FIG. 9 shoWs the UV absorption spectra of topotecan 
lactone (left panel) and CPT-11 lactone (right panel) in the 
absence and presence of duplex DNAoligonucleotides ((dG 
dC)15 or (dA-dT)15) in PBS (pH 500x005 at room 
temperature). Drug, (dG-dC)15, and (dA-dT)15 concentra 
tions of 10 pM, 16 mM base, and 24 mM base, respectively, 
Were employed. 
FIG. 10 shoWs NMR spectra depicting the titration of (A) 
CPT-11 to d(CGTACG) at pH 7.0, 20° C. and (B) TPT 
lactone to d(CGTACG) at pH 5 at 20° C. The ratios shoWn 
in the ?gure are for drug/DNA. 
FIG. 11 contrasts the changes in the 1H NMR resonances 
for both free drug and nascent DNA versus 2:1 drug DNA 
complexes. Not hoW the chemical resonances of both the 
drug and DNA shift up?eld upon complex formation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Camptothecin drugs are a family of agents Which exhibit 
very high potencies against a Wide and diverse range of 
tumor types and thus camptothecin drugs are useful anti 
cancer agents. LikeWise, oligonucleotides can be used as 
effective anticancer drugs. Cancer has been shoWn to be a 
somatic genetic disorder With gene dysfunctions that accu 
mulate as the tumor progresses from premalignant lesions to 
malignant transformations. Oligonucleotides containing 
genetic information can be transferred to speci?c target cells 
in the body to prevent and limit the spread of cancer cells. 
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This technology, Widely referred to as gene therapy, requires 
the oligonucleotide or genes and their regulatory elements as 
Well as vectors such as cationic liposomes or adenoviruses 
to introduce the genes into the patients target cells for 
therapeutic activity. 
There are several reasons Why combination camptothecin 
drug-gene therapy dosage forms may prove to be promising 
technologies for cancer treatment. Hematologic malignan 
cies and solid tumors contain cells that are highly responsive 
to the presence of camptothecin drugs. As a result of the 
stable delivery of the bioactive lactone forms of camptoth 
ecin drugs facilitated by the presence of the oligonucleotide, 
tumor siZe can be reduced and the spread or metastasis of the 
tumor can be halted. A number of genetic mechanisms of 
cancer development and progression have been discovered, 
leading to genetic, oligonucleotide-based therapies for treat 
ment. The combination of the tWo therapeutic substances, 
active lactone camptothecin drugs and oligonucleotides, 
provide signi?cant advantages at inhibiting the progression 
of solid tumors and hematologic malignancies. Whereas the 
camptothecin drugs can destroy cancer cells by inhibiting 
the proper function of topoisomerase I enZyme, 
oligonucleotide-based gene therapy can potentially augment 
the camptothecin therapy by modulating cytokine/ 
immunotherapy, drug sensitivity genes, tumor suppressor 
genes, and drug resistance genes, and genes involved in 
angiogenesis. While the presence of the oligonucleotide 
serves as a stabiliZing matrix Where noncovalent binding 
interactions stabiliZe the camptothecin drug in the active 
lactone form, the oligonucleotide also can have a therapeutic 
effect that can enhance, prolong, and have a desirable 
combined effect With the camptothecin drug. Other objects 
and advantages of the present invention involving 
oligonucleotide-camptothecin drug formulations Will 
become apparent as to the description thereof proceeds. 
Typically, viral or non-viral vectors are used to deliver the 
gene therapy oligonucleotides to target cancer cells. The 
viral vectors include the folloWing: retroviruses, 
adenoviruses, adeno-associated viruses, Herpes viruses, 
Vaccinia viruses, and polioviruses. The non-viral vectors 
include transfection, naked DNA injection, gene gun, direct 
injection, cationic liposomes, virosomes, and receptor 
mediated delivery vehicles. Each of the above gene therapy 
vectors contain oligonucleotides Which can act to stabiliZe 
the camptothecin drug. The vectors thus serve as a means of 
delivering stable camptothecin drug to target tissue. The 
combination of stable camptothecin drug and gene therapy 
has potentially unique and desirable consequences on 110 
inhibiting the spread of cancer in humans and animals. 
Of the non-viral and viral vectors, liposomes and cationic 
lipids have the advantage of being safe, readily reproducible 
and easy to manufacture. Liposomes containing oligonucle 
otides can more effectively stabiliZe the camptothecin drug 
in the antitumor-active lactone form. Oligonucleotide 
containing liposomes provide a convenient mode of delivery 
for combination therapy comprising chemotherapy/gene 
therapy. 
In satisfaction of the foregoing objects and advantages, 
there is provided by this invention oligonucleotide compo 
sitions for delivery of camptothecin drugs. Those composi 
tions comprise at least one camptothecin drug in complex 
formation With an oligonucleotide including DNA and RNA 
so that the camptothecin drug contains a stabiliZed lactone 
ring. Additionally, the compositions include components 
Which comprise viral and non-viral vectors such as proteins, 
lipids, and carbohydrates. 
Oligonucleotides 
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The oligonucleotide Which stabiliZes the camptothecin 
drug of interest can be any of the folloWing general types: 
B-Form DNA, A-Form DNA, C-Form DNA, D-Form DNA, 
T-Form DNA, Z-DNA, double-stranded DNA: single 
stranded DNA, negatively-supercoiled DNA, nicked DNA, 
positively-supercoiled DNA, plasmid DNA, circular or 
cDNA, interWound or toroidal coiled DNA, catenaned or 
knotted DNA, helical DNA, hairpin DNA, interstrand 
crosslinked DNA, DNA in Cruciform structures, intermo 
lecular triplex DNA, intramolecular triplex DNA, four 
stranded DNA, Anisomorphic DNA, genomic DNA, nucleo 
somal DNA, chromosomal DNA, antisense 
oligonucleotides, riboZymes, triplex-forming 
oligonucleotides, nuclease-resistant DNA therapeutics, self 
assembled oligonucleotides as antisense agents, circular 
oligonucleotides, peptide nucleic acids, stabiliZed RNA ana 
logs for antisense and riboZyme applications, phosphodi 
ester and chimeric oligonucleotides, protein-antisense oli 
gonucleotide conjugates, antibody-antisense 
oligonucleotide conjugates, messenger RNA, Hoogsteen 
DNA, phosphorothioate oligonucleotides, phosphodiester 
oligonucleotides, methylphosphonate oligonucleotides, 
alphavirus DNA, mitochondrial DNA, DNA plasmid shuttle 
vectors, hammerhead riboZymes, hairpin riboZymes, oligo 
nucleotide cleaving riboZymes, antisense RNA, viral vector 
DNA, pararetroviral and retroviral DNA, N-linked oligosac 
caride DNA, self-splicing group 1 intron riboZymes, self 
splicing group II intron riboZymes, ribonuclease P(RNAase 
P) riboZyme, hepatitis delta virus riboZymes, hairpin 
riboZymes, anti-HIV riboZymes, raf 
oliogdeoxyribonucleotide, and catalytic DNA. 
The nucleic acids Which are useful in the present inven 
tion are those that form drug-oligonucleotide complexes in 
solution as Well as those that form drug-oligonucleotide 
complexes in non-viral or viral delivery vehicles. The 
nucleic acids are typically nucleotide polymers having from 
10 to 500,000 nucleotide residues. Typically, the nucleic 
acids of interest are to be administered to a subject for the 
purpose of repairing or enhancing or diminishing the expres 
sion of a cellular protein. In addition, the nucleic acid 110 
may carry a label (e.g. radioactive label, ?uorescent label or 
calorimetric label), these labels serving the purpose of 
providing clinical diagnosis relating to the presence or 
absence of complementary nucleic acids. Accordingly, the 
nucleic acids or nucleotide polymers can be nucleic acid 
polymers including genomic DNA, cDNA, mRNA or oli 
gonucleotides containing nucleic acid analogs. An example 
of these molecules is provided by the antisense derivatives 
as summariZed in a recent revieW (Stein et al., Science 
261:1004—1011 (1993) and in US. Pat. Nos. 5,264,423 and 
5,276,019, the disclosures of Which are incorporated herein 
by reference. Still further, the nucleic acids may encode 
transcriptional and translational regulatory sequences 
including promoter sequences and enhancer sequences 
Within the oligonucleotide. 
The nucleotide polymers can be single-stranded DNA or 
RNA, or double-stranded DNA or DNA-RNA hybrid mol 
ecules. Examples of double-stranded DNA include structural 
genes or genes including control and termination regions, or 
self-replicating systems such as plasmid DNA. 
Examples of single-stranded nucleic acids include anti 
sense oligonucleotides (complementary to DNA and RNA), 
riboZymes and triplex-forming oligonucleotides. 
Approaches to enhancing the chemical stabilities of oligo 
nucleotides have been developed. For enhance stabilities the 
single-stranded nucleic acids Will preferably have some or 
all of the nucleotide linkages substituted With stable, non 
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phosphodiester linkages. Such substitutions include 
phosphorothioate, phosphorodithioate, phosphoroselenate, 
or O-alkyl phosphotriester linkages. 
The nucleic acids used in the present invention may also 
involve nucleic acids in Which modi?cations have been 
made in one or more sugar moieties and/or in one or more 
of the pyrimidine or purine bases. Sugar modi?cations can 
include replacement of one or more hydroxyl groups With 
halogens, alkyl groups, aZido groups or functionaliZed as 
ethers or esters, and amines. Additionally, complete replace 
ment of the sugar moiety may be carried out resulting in 
sterically and electronically similar structures, including 
aZa-sugars and carbocyclic sugar analogs. Examples of 
modi?cations in the purine or pyrimidine base moiety 
include, for example, alkylated purines and pyrimidines, 
acylated purines or pyrimidines, or other heterocyclic sub 
stitutes knoWn to those of skill in the art. 
Our innovation can also use multiple genetic sequences. 
In this manner, the sequences for different proteins may be 
located on one strand or plasmid. Promoter, enhancer, stress 
or chemically-regulated promoters, antibiotic-sensitive or 
nutrient-sensitive regions, as Well as therapeutic protein 
encoding sequences, may be included into the oligonucle 
otide of interest as required. Non-encoding sequences can 
also be included in the oligonucleotide of interest. 
The nucleic acids employed in the present invention can 
be isolated from natural sources, or obtained from sources 
such as the ATCC or GenBank collections of compounds, or 
the nucleic acids can be prepared either by manual or 
automated synthetic methods. Synthetic nucleic acids can be 
prepared by a variety of solution or solid-phase reaction 
schemes. In general, solid-phase synthesis is the preferred 
method. Detailed descriptions of the procedures for solid 
phase synthetic methodologies of nucleic acids by 
phosphite-triester, phosphotriester, and H-phosphonate 
chemistries are noW Widely available through out the litera 
ture. Examples of solid-phase synthetic methods of nucleic 
acids can be found in the folloWing references: Itakura, US. 
Pat. No. 4,401,796; Caruthers, et al., US. Pat. Nos. 4,458, 
066 and 4,500,707; Beaucage, et al., Tetrahedron Lett, 
22:1859—1862 (1981); Matteucci, et al., J. Am. Chem. Soc., 
103:3185—3191 (1981); Caruthers, et al., Genetic 
Engineering, 4:1—17 (1982); Jones, chapter 2, Atkinson, et 
al., chapter 3, and Sproat, et al., chapter 4, in Oligonacle 
otide Synthesis. A Practical Approach, Gait (ed.), IRL Press, 
Washington DC. (1984); Froehler, et al., Tetrahedron Lett, 
27:469—472 (1986); Froehler, et al., Nucleic Acids Res., 
14:5399—5407 (1986); Sinha et al. Tetrahedron Left, 
24:5843—5846 (1983); and Sinha, et al., Nucl. Acids Res., 
12:4539—4557 (1984). 
Nucleic acids Which When introduced into animals or 
humans provide physiological effects are included in this 
invention. In this manner nucleic acids can be selected for 
speci?c therapeutic outcomes that complement or enhance 
the therapeutic bene?t Which is achieved by 
co-administration of the oligonucleotide-stabiliZed camp 
tothecin. 
An example of hoW nucleic acid-camptothecin drug 
co-administration can be therapeutic is given by the admin 
istration of a camptothecin drug With an anti-angiogenic 
oligonucleotide. Upon reaching the tumor site the camptoth 
ecin drug can exert its cytotoxic effect and thereby reduce 
the tumor siZe by destroying cancer cells. A major cause of 
cancer is often the regroWth of the tumor folloWing the ?rst 
round of chemotherapy. The regroWth of a tumor folloWing 
a course of chemotherapy has been frequently attributed to 
vasculariZation of the tumor site, a process Which brings 
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nutrients to the tumor Which in turn facilitates regroWth of 
the tumor. Thus it may be considered therapeutically desir 
able to treat a patient With anti-angiogenic compounds 
folloWing reduction of tumor siZe With camptothecin che 
motherapy. 
Genetic material of choice Would be an oligonucleotide 
Which sloWs or eliminates the angiogenic process. Such a 
therapeutic approach could involve the use of an oligonucle 
otide that reduces or prevents the expression of a key 
angiogenic protein. Or the oligonucleotide approach could 
include genes encoding anti-angiogenic polypeptides either 
absent or produced in diminished quantities in the cancer 
patient being treated. The nucleic acids could also reverse 
the expression of mutant, non-functional forms of anti 
angiogenic proteins. Additionally it may be of interest to use 
oligonucleotides such as DNA encoding polypeptides for 
secretion from target cells so as to provide for a systemic 
effect by the protein encoded by the DNA. Speci?c DNA 
molecules of interest include those encoding hemoglobin, 
interleukin-1, interleukin-2, interleukin-3, interleukin-4, 
interleukin-4, interleukin-5, interleukin-6, interleukin-7, 
interleukin-8, interleukin-9, interleukin-10, interleukin-11, 
etc., GM-CSF, G-CSF, M-CSR, human groWth factor, 
insulin, factor VIII, factor IX, tPA, a variety of nuclear 
binding proteins and DNA topology modifying enZymes 
such as topoisomerases I, topoisomerase II, topoisomerase 
III, LDL receptors, tumor necrosis factor, PDGF, EGF, NGF, 
EPO, [3-globin and the like, as Well as biologically active 
mutants of these proteins. The nucleic acid utiliZed may also 
be antisense DNA or RNA. These antisense molecules can 
bind to naturally-occurring DNA or RNAWithin the host and 
block the production of molecules Which can counteract, 
overcome, or negate the pharmacological effects achieved 
by the administration of camptothecins administered in 
oligonucleotide-stabiliZed form. 
Further to this concept of co-administration of cytotoxic 
camptothecins and anti-angiogenic oligonucleotides, pre 
vention of blood vessel groWth could be achieved by modu 
lating the levels of the numerous types of groWth factors and 
proteins involved in the angiogenesis process [Folkman, et 
al., Science, 235:442—447 (1987)]. These key angiogenic 
components include, for example, acidic and basic ?broblast 
groWth factors (alpha-FGF and beta-FGF), vascular endot 
helial groWth factor (VEGF), epidermal groWth factor 
(EGF), transforming groWth-factor ot- and [3-(TGF-[3 and 
TGF-B), platelet-derived endothelial cell groWth factor (PD 
ECGF), platelet-derived groWth factor (PDGF) itself, tumor 
necrosis factor ot-(TNF-ot), hepatocyte groWth factor (HGF) 
and insulin like groWth factor [See, Klagsbrun, et al., Anna. 
Rev Physiol., 53:217—239 (1991) and Folkman, et al., J. 
Biol. Chem. 267:10931—10934 (1992)]. VEGF, or its alter 
nate designation vascular permeability factor (VPF), has 
also been implicated in the angiogenesis process, and oli 
gonucleotides co-administered With camptothecins may also 
be useful in modulating VEGF levels and optimiZing the 
anticancer effects of the camptothecins. VEGF is a key 
angiogenic protein. Evidence that VEGF stimulates the 
angiogenesis in vivo had been developed in experiments 
performed on rat and rabbit cornea (Levy, et al., Growth 
Factors, 2:9—19 (1989) and Connolly, et al., J. Clin Invest, 
84:1470—1478 (1989)), the chorioallantoic membrane 
(Ferrara, et al., Biochem Biophys Res Commun., 
161:851—855 (1989)), and the rabbit bone graft model. 
Connolly, et al., J Clin Invest, 84:1470—1478 (1989). The 
nucleotide sequence of numerous peptides and proteins, 
including angiogenic proteins such as VEGF, are readily 
available through a number of computer data bases, for 
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example, GenBank, EMBL and SWiss-Prot. Through gene 
therapy methods, the levels of proteins involved in the 
angiogenic process can be modulated and the activities of 
oligonucleotide-stabiliZed camptothecin drug delivery 
vehicles optimiZed for gains in therapeutic outcomes for the 
cancer patients. 
Antisense RNA molecules can also potentially be used to 
optimiZe the therapeutic activities of the camptothecin drugs 
delivered to the body in a stable form by complexing With 
oligonucleotide. Antisense RNA molecules are knoWn to be 
effective at regulating translation Within the cell. Using 
knoWn methods antisense RNA molecules can be produced 
from the corresponding gene sequences. The antisense mol 
ecules can be used as a therapeutic to regulate gene expres 
sion that optimiZes camptothecin activity Within the body. 
The antisense molecules are typically designed by studying 
the nucleotide sequence, and by reversing the orientation of 
the coding region With regard to the promoter. Accordingly, 
the antisense RNA is complementary to the corresponding 
mRNA. RevieWs of antisense design can be found elseWhere 
[Green, et al.,Ann. Rev. Biochem. 55:569—597 (1986)]. The 
antisense sequences can contain modi?ed sugar phosphate 
backbones Which is a Widely used approach that alloWs for 
the increased stabilities of the antisense molecules folloWing 
their introduction into humans or animals. The changes in 
the antisense RNA can also be used to make the antisense 
molecules less sensitive to RNase activity. Examples of 
these types of antisense modi?cations are described by 
Rossi, et al., Pharmacol, Ther 50(2):245—354, (1991). 
Co-complexation of camptothecin drugs With multidrug 
resistance (MDR) and/or multidrug resistance-associate pro 
tein (MRP) antisense RNAs Would result in the camptoth 
ecin drugs proving to be cytotoxic to the cancer cells and the 
riboZymes Would prevent drug resistance from advancing at 
the tumor site. Methods for the preparation and use of MDR 
and MRP antisense RNAs to modulate drug resistance have 
been reported previously (Gao et al., Anticancer Res. (1998) 
18:4 3073—6). 
Viral Delivery Vectors 
Viral or non-viral vectors can be used to deliver the 
oligonucleotide-camptothecin drug complexes to the target 
cells. The viral vectors can include the folloWing: 
retroviruses, adenoviruses, adeno-associated viruses, Herpes 
viruses, Vaccinia viruses, and polioviruses. 
Retroviruses contain RNA and DNA. The RNA genome 
consists of tWo 8500-nucleotide RNA molecules nonco 
valently bonded to one another. The virus is enclosed by a 
lipid bilayer. Hence the retrovirus can serve as vehicle for 
delivering of oligonucleotides to the body, but also as a 
vehicle Where camptothecin drugs can be introduced, stored 
and delivered in a stable manner While being bound in the 
active lactone form to the oligonucleotides contained in the 
retrovirus. Addition of cationic lipids to retroviruses could 
augment the delivery of the drug and oligonucleotide con 
tent to cancer cells. In a similar manner, adenoviruses, 
SV40, Herpes viruses, Vaccinia viruses, Parvoviruses, 
Reoviruses, In?uenza viruses, Vesicular stomatitis virus, 
Sindbis virus, poliomyelitis virus, human Wart virus, aden 
ovirus are all viruses that contain oligonucleotides that can 
serve the multiple roles of complexing, stabiliZing, 
transporting, and delivering camptothecin drugs in humans 
and animals While also delivering oligonucleotides that are 
capable of inducing pharmacological effects that differ from 
the camptothecin drugs. The pharmacological effects of the 
oligonucleotides contained in the virus particles can 
augment, complement and provide synergism With the 
camptothecin drug therapy. 
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Non-Viral Delivery Vectors 
The non-viral vectors include transfection, naked DNA 
injection, gene gun, direct injection, cationic liposomes, 
virosomes, and receptor-mediated delivery vehicles. Each of 
the above gene therapy vectors contain oligonucleotides 
Which can act to stabiliZe the camptothecin drug of interest. 
The vectors thus serve as a means of delivering stable 
camptothecin drug to target tissue. The combination of 
stable camptothecin drug and gene therapy has potentially 
unique and desirable consequences on inhibiting the spread 
of cancer in humans and animals. 
To simplify the manipulation and handling of the DNA, 
prior to introduction into animals and humans, the DNA is 
preferably inserted into a vector, e.g., a plasmid vector such 
as pUC118, pBR322, or other knoWn plasmid vectors 
[Sambrook, et al., Molecular Cloning: A Laboratory 
Manual, Cold Spring Harbor Laboratory press, (1989)]. The 
plasmid vector may also include a selectable marker such as 
the [3-lactamase gene for ampicillin resistance, provided that 
the marker polypeptide does not adversely effect the 
metabolism of the organism being treated. Additionally, if 
necessary, the DNA may be operably linked to a promoter/ 
enhancer region capable of driving expression of the protein 
in the target cell of interest. An example of an appropriate 
promoter is the cytomegalovirus (CMV) promoter. 
Normally, an enhancer is not necessary When the CMV 
promoter is used. Other promoters may be used as Well. 
Certain proteins can be expressed using their native pro 
moter. 
In certain situations, it may be desirable to use DNA that 
encodes tWo or more different proteins in order to optimiZe 
the therapeutic outcome. For example, anti-angiogenic oli 
gonucleotides can be combined With other genes or their 
encoded gene products to enhance the activity of targeted 
cells to camptothecin-based therapies. 
Liposomes and cationic liposomes have been Widely used 
to deliver DNA and antisense oligonucleotides to target 
tissues. Here We claim as a vehicle for oligonucleotide 
stabiliZed camptothecin drug delivery a liposome or micelles 
having at least one membrane comprised of surfactant, lipid 
or mixture thereof Wherein the membrane de?nes a closed 
compartment for holding the camptothecin drug and oligo 
nucleotide complex. In this compartment the lactone ring of 
the camptothecin drug is protected from hydrolysis and fully 
stabiliZed by contributions made by the presence of the 
oligonucleotide. The oligonucleotide utiliZed in the present 
invention is selected from a group consisting of DNA and 
RNA, as Well as mixtures thereof. Any of the oligonucle 
otides mentioned elseWhere in this document could be 
included in the liposomal preparations. 
The present invention provides novel, lipid 
oligonucleotide-camptothecin drug particles. The liposomes 
may comprise synthetic phospholipids, phosphatidic acids, 
phosphatidylethanolamines, phosphatidylgylcerols, 
phosphatidylserines, polymeriZable phospholipids, phos 
pholipid such as egg phosphatidylcholine, hydrogenated soy 
phosphatidylcholine, distearoylphosphatidylcholine, 
dimyristoylphosphatidylcholine, 
distearoylphosphatidylcholine, or 
diarachidonoylphosphatidylcholine, and may additionally 
comprise cholesterol, for example, in about a 55:45 to 75:25 
phospholipid:cholesterol mol ratio. The liposomes may 
additionally comprise alpha tocopherol. The liposomes can 
be about 30 nm to about 10 microns in siZe, preferably about 
100 to about 300 nm in diameter. The technology can 
include large unilamellar vesicles or multilamellar 
liposomes, or complexes of varying shapes as Well. They can 
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contain about 0.05 to 200 mg/ml lipid, more preferably 
about 5 to about 110 mg/ml lipid. The entrapment of the 
oligonucleotide-camptothecin drug complex in the lipo 
somes is from about 50% to about 100%, preferably about 
90% to about 100%, more preferably about 98 to about 
100%. These liposome may be large unilamellar vesicles or 
multilamellar particles. The liposomes may be homoge 
neous or unimodal With regard to siZe distribution. 
Pharmaceutical preparations containing the 
oligonucleotide-camptothecin drug complex entrapped in 
the liposomes and pharmaceutically acceptable carriers or 
diluents are another embodiment of the present invention. 
The liposome compositions of the invention may be used to 
treat cancer. In related applications, the liposomal formula 
tions can be used prophylactically to prevent the onset or 
recurrence of a cancer. The composition of the present 
invention is, for example, provided also as a three 
component system. The three component system comprises 
empty liposomes in a solution ranging from about pH 3.0 to 
pH 8.0, and the oligonucleotide-camptothecin drug com 
plex. The solution can be acetic acid buffer, oxalic acid 
buffer, or succinic acid buffer, preferably aqueous citric acid 
buffer. The basic solution is preferably sodium carbonate. 
The complex to lipid Weight ratio is greater than about 0.1:1 
to about 3:1. 
PolymeriZable phospholipids that can be used in this 
include polymeriZable double-bond containing monomeric 
phospholipids. The polymeriZable phospholipids to be used 
in this invention must contain at least one polymeriZable 
moiety, but may include several polymeriZable groups as 
Well. PolymeriZable groups located in the phospholipids can 
contain, but need not be limited to, the following: 
diacetylenes, ole?ns, acetylenes, and thiols as Well. The 
polymeriZation process can be initiated by free radical 
initiators such as aZo-bis-isobutyronitrile (AIBN) or other 
initiators as Well including aZo-bis-amidinopropane 
dihydrochloride). Other methods of initiating polymeriZa 
tion include using ultraviolet light or gamma irradiation. 
The liposome compositions may be prepared by remote 
loading techniques, Which rely on a pH or chemical gradient 
across the liposome bilayer to load camptothecin drugs into 
liposomes containing oligonucleotide-camptothecin drug 
complexes isolated or in contact With the lipid matrix. A?rst 
step Would involve forming the oligonucleotide-containing 
liposomes in a aqueous medium, preferably a buffer. The 
solution outside the liposomes is then exchanged or modi 
?ed by acidifying or alkaliniZing the medium, thereby 
establishing a pH or chemical gradient. Care is taken not to 
subject the liposomal particles to osmotic stress through 
these manipulations. The resulting liposomes are then 
admixed With the camptothecin drugs, Which can be pre 
pared by contacting the liposomal-oligonucleotide solution 
and camptothecin drug solution, or liposome compositions 
may be prepared from oligonucleotide-camptothecin drug 
complex and lipids in either detergent-based or organic 
solvent-based systems, folloWed by removal of the detergent 
or organic solvent, leading to particle formation. 
The liposomes of the invention may be dehydrated, either 
prior to or folloWing the establishment of the remote loading 
techniques, Which rely on a pH (Biochim. Biophys. Acta, 
857, 123, 1986) or chemical gradient (J. Natl. Cancer Inst, 
81, 1484, 1989). Thus, the present invention provides meth 
ods of preparing oligonucleotide-camptothecin drug par 
ticles Which are useful for the therapeutic delivery of oli 
gonucleotide and camptothecin drugs for combination 
therapy. Within a liposomal formulation both the oligonucle 
otides and oligonucleotide-camptothecin drug complexes 
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become protected from degradation. The liposomes thus 
formed are suitable for pharmaceutically acceptable liposo 
mal formulations Which alloW direct parenteral administra 
tion of lactone stable oligonucleotide-camptothecin drug 
complexes to human patients With cancer. Pharmaceutically 
acceptable liposomal formulations Which alloW the direct 
oral administration of oligonucleotide-camptothecin drug 
complexes to human patients With cancer and other disease 
states are also claimed in the current invention. 
Brie?y, one method of forming lipid-oligonucleotide 
camptothecin drug particles involves contacting an oligo 
nucleotide solution and a camptothecin drug solution to 
form a oligonucleotide-camptothecin drug complex solution 
then contacting that oligonucleotide-camptothecin drug 
complex solution With a solution of lipids and a detergent to 
form a oligonucleotide-camptothecin drug-lipid mixture, 
folloWed by removal of the detergent or organic solvent. 
Another method involves ?rst forming the liposomes con 
taining oligonucleotide in aqueous medium, preferably a 
buffer, then acidifying or alkaliniZing the medium, thereby 
establishing a pH or chemical gradient. The resulting lipo 
somes are then admixed With a solution containing lipophilic 
camptothecin drugs that can partition into the pre-formed 
particles or ioniZable, amine-containing camptothecin drugs 
that can accumulate in the liposomal particle in response to 
the ion gradient across the liposomal membrane. Another 
method of forming lipid-nucleic add particles involves the 
folloWing: 1) contacting an amount of cationic lipids With 
oligonucleotide-camptothecin drug complex in a solution; 2) 
the solution comprising of from about 15—35% Water and 
about 65—85% organic solvent and the amount of cationic 
lipids being sufficient to produce a +/— charge ratio of from 
about 0.1 to about 200. 
To provide a hydrophobic, charge-neutraliZed lipid 
oligonucleotide-camptothecin drug complex, the folloWing 
procedure can be used: contacting the hydrophobic, charge 
neutraliZed lipid-oligonucleotide-camptothecin drug com 
plex in solution With non-cationic lipids, to provide a 
lipid-oligonucleotide-camptothecin drug complex mixture; 
and removing the organic solvents from the lipid 
oligonucleotide-camptothecin drug complex mixture to pro 
vide lipid-oligonucleotide-camptothecin drug complex par 
ticles in Which the nucleic acids are protected from 
degradation and the oligonucleotide-drug complexes aid in 
stabiliZing the drug. 
The folloWing lipids can be used in the formation of 
camptothecin-lipid-oligonucleotide complexes: DC-Chol, 
3B-(N—(N‘,N‘-dimethylaminoethane)carbamoyl) 
cholesterol (see, Gao, et al., Biochem. Biophys. Res. Comm. 
179;2s0_2s5 (1991)); DDAB, N,N-distearyl-N,N 
dimethylammonium bromide; DMRIE, N-(1,2 
dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl 
ammonium bromide; DODAC, N,N-dioleyl-N,N 
dimethylammonium chloride; DOGS, diheptadecylami 
doglycyl spermidine; DOPE, 1,2-sn 
dioleoylphoshatidylethanolamine; DOSPA, N-(1-(2,3 
dioleyloxy)propyl)-N-(2-(sperminecarboxamido)ethyl)-N, 
N-dimethylammonium tri?uoroacetate; DOTAP, N-(1-(2,3 
dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride; 
DOTMA, N-(1-(2,3-dioleyloxy)propyl)-N,N,N 
trimethylammonium chloride; ESM, egg sphingomyelin. 
The term “lipid” refers to any suitable material resulting in 
macromolecular assembly such as bilayer, monolayer, lipid 
DNA complex, such that a hydrophobic portion of the lipid 
material orients toWard the monolayer, bilayer, or DNA 
lipid complex While a hydrophilic portion orients toWard the 
aqueous phase. Amphipathic lipids are necessary for the 
US 6,897,200 B1 
15 
formation of the primary lipid vesicle structural element. 
Hydrophilic characteristics of these agents derive from the 
presence of phosphate, carboxylic, sulfato, amino, 
sulfhydryl, nitro, and other similar functionalities. Hydro 
phobicity in the lipids can be conferred by the inclusion of 
groups that include, but are not limited to, long chain 
saturated and unsaturated aliphatic hydrocarbon groups, and 
groups substituted With one or more aromatic, cycloaliphatic 
or heterocyclic groups. The term “neutral lipid” refers to any 
of a number of lipid species Which exist either as uncharged 
or neutral ZWitterionic species at physiological pH. The 
group of neutral lipids are comprised of amphiphiles such as 
diacylphosphatidylcholine, 
diacylphosphatidylethanolamine, ceramide, sphingomyelin, 
cephalin, and cerebrosides. 
The term “non-cationic lipid” refers to any neutral lipid as 
described above as Well as anionic lipids. Examples of 
anionic lipids include the folloWing: cardiolipin, diacylphos 
phatidylserine and diacylphosphatidic acid. The term “cat 
ionic lipid” refers to any of a number of lipid species Which 
carry a net positive charge at physiological pH. Such lipids 
include, but are not limited to, DODAC, DOTMA, DDAB, 
DOTAP, DC-Chol and DMRIE. Additionally, a number of 
commercial preparations of cationic lipids are available 
Which can be used in the present invention. These include, 
for example, LIPOFECTIN (commercially available cat 
ionic liposomes comprising DOTMA and DOPE, from 
GIBCO/BRL, Grand Island, N.Y., USA); LIPO 
FECTAMINE (commercially available cationic liposomes 
comprising DOSPA and DOPE, from GIBCO/BRL); and 
TRANSFECTAM (commercially available cationic lipids 
comprising DOGS in ethanol from Promega Corp., 
Madison, Wis, USA). This invention can also employ 
polymeriZable phospholipids Where polymeriZable moieties 
are included in the headgroup region of the phospholipid 
and/or in the acyl chain region of the phospholipid. 
The term “transfection” as used herein, refers to the 
introduction of polyanionic materials, particularly nucleic 
acids, into cells. The term “lipofection” refers to the delivery 
of such materials using liposome complexes to cells. The 
polyanionic materials can be in the form of RNA or DNA 
incorporated into expression vectors. The involvement of 
expression vectors facilitates gene expression folloWing 
entry into the cell. Polyanionic material can be used in the 
present invention and is meant to include oligonucleotides 
having coding sequences for structural proteins, receptors 
and hormones, as Well as transcriptional and translational 
regulatory elements (i.e., promoters, enhancers, terminators 
and signal sequences) and vector sequences. Incorporation 
of particular nucleic acids into expression vectors are knoWn 
methods to those of skill in the art, but are described in detail 
elseWhere, for example: Sambrook et al., Molecular Clon 
ing.'A Laboratory Manual (2nd ed.), Vols. 1—3, Cold Spring 
Harbor Laboratory, (1989) or Current Protocols in Molecu 
lar Biology, F. Ausubel et al., ed. Greene Publishing and 
Wiley-Interscience, NeW York (1987), both of Which are 
incorporated herein by reference. The terms “expression 
vectors”, “cloning vectors”, or “vectors” are used to refer to 
plasmids or other nucleic acid-derived materials that are able 
to replicate in a chosen host cell. Expression vectors may 
replicate autonomously, or they may replicate by being 
inserted into the genome of the host cell, and these methods 
are Well knoWn to those experienced in the art. Vectors that 
replicate autonomously Will have an origin of replication or 
autonomous replicating sequence (ARS) that is functional in 
the target cells and tissues of interest. Often, it is desirable 
for a vector to be usable in a variety of cell types, e.g., 
particularly in mammalian cells. 
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The term “hydrophobic” as applied to DNA and DNA 
complexes implies complexes Which are substantially more 
soluble in organic solvents than in aqueous solutions. More 
particularly, hydrophobic DNA and DNA complexes are 
aggregates Which are at least 40% soluble in organic sol 
vents such as chloroform/methanol mixtures, and preferably 
more than 80% soluble, more preferably more than 90% 
soluble in such organic solvents. 
The current invention can employ formulations With 
lipids exhibiting different transition temperatures and 
vesicles siZes. Multilamellar vesicles (MLVs), large unila 
mellar vesicles (LUVs), and small unilamellar vesicles 
(SUVs) at concentrations ranging from 0.5 mg/ml to 200 
mg/ml can be prepared through a hydration process. Lyo 
philiZed formulations of liposomal oligonucleotide 
camptothecin drug-lipid can be employed in this invention 
as Well. Vials containing the oligonucleotide-camptothecin 
drug-lipid complexes Will be obtained by freeZe-drying 
solutions containing these ingredients in mixtures of 
t-butanol and Water (drug:lipid ratios in the range of 1:10 to 
1:200 Would be desirable). In light of the high levels of 
lipophilicity that We have observed in some of the neW 
analogues (KDMPC=8,000 M-1 versus KDMPC=1M_1 for 
other camptothecins), the camptothecin drugs Will have the 
ability to interact With the liposomal particles in a number of 
different Ways, dependent upon the individual drug struc 
ture. FolloWing lyophiliZation, the liposomes for i.v. admin 
istration Will be reconstituted by adding PBS to the vial 
containing lyophiliZed particles and mixing for several min 
utes. 
The folloWing lipid combinations and particle types are 
suitable for use in this invention: Egg-PC/Cholesterol (SUV, 
LUV and MLV); DPPC/DPPG/cholesterol (SUV, LUV and 
MLV ratio 8:5:4 or thereabout); DPPC/DPPG (SUV, LUV 
and MLV; lipid ration of 5:2 or thereabout); DMPC:DMPG 
(SUV, LUV, MLV; lipid ratio of 14:1 or thereabout); Egg 
PC/Egg PG/Cholesterol (SUV, LUV and MLV; lipid ratios 
of 4:2:1 or thereabout); DSPC/DSPG/gm 1/Sphingomyelin 
Cholesterol (SUV and MLV; ratio 8:5:4:1:1 or thereabout); 
DPPC/DPPA (SUV and MLV; lipid ratio of 5:6:2 or 
thereabout); DMPC:DMPA (SUV, LUV, MLV; lipid ratio of 
14: 1 or thereabout); HPC/PEG (MLV and SUV; lipid ratio of 
5:1 or thereabout); Egg-PG/Cholesterol (SUV, LUV and 
MLV; lipid ratio 2:1 or thereabout); DPPG/cholesterol 
(SUV, LUV and MLV ratio 8:4 or thereabout); DPPG/DPPA 
(SUV, LUV and MLV; lipid ration of 5:1 or thereabout); 
DMPC:DSPC (SUV, LUV, MLV; lipid ratio of 14:1 or 
thereabout); Egg-PC/Egg PG/Cholesterol/DPPA (SUV, 
LUV and MLV; lipid ratios of 4:2:1:1 or thereabout); 
DMPC/DSPC/Sphingomyelin/Cholesterol (SUV, LUV and 
MLV; ratio 8:5:4::1 or thereabout); DPPC/egg PE (SUV, 
LUV and MLV; lipid ratio of 5:2 or thereabout); DMPC:D 
MPA:DSPC (SUV, LUV, MLV; lipid ratio of 14:1:3); HPC/ 
cholesterol (MLV, LUV and SUV; lipid ratio of 5:1 or 
thereabout). 
The drug/lipid mixtures can be prepared in a suitable 
solvent such as chloroform and then dried under a stream of 
nitrogen gas. Lipid ?lms resulting from this process can then 
be dried under high vacuum for 1—24 hrs. to properly assure 
the removal of trace chloroform. Dried lipid/drug ?lms can 
be hydrated in solutions of varying pH values. In some cases 
liposome preparations can be froZen/thaWed several times 
prior to extrusion through stacked polycarbonate ?lters of 
speci?c pore siZe to reduce the particle siZe. In some cases 
MLVs Will be sonicated to prepare small MLVs and SUVs. 
During formulations samples can be heated to approxi 
mately 1 to 10° C. above the thermotropic phase transition 
US 6,897,200 B1 
17 
temperatures of the phospholipids contained in the prepa 
rations prior to the extrusion or sonication process. Particle 
sizing of the preparations can be performed using commer 
cially available particle siZers such as instruments made by 
Malvern or Coulter. 
Cationic Amphiphiles and Polyamines 
The cationic amphiphiles are often effective at transport 
ing biologically-active therapeutics into cells. Additionally, 
targeting of organs for gene therapy by intravenous admin 
istration of therapeutic compositions can be achieved using 
such systems (as described in US. Pat. No. 5,719,131). 
Lipophilic groups of amphiphiles can be derivatives of 
steroids, functionaliZed amines, or derived from alkyl or 
acyl groups; and the cationic groups can by amines of 
modi?ed amines, or polyalkylamines, Which may be proto 
nated at physiological pH. The therapeutic formulations are 
prepared by contacting a dispersion of cationic amphiphiles 
With the biologically-active molecules: in the present inven 
tion described herein it is camptothecin drugs in combina 
tion With DNA. Oligonucleotide-camptothecin drug com 
plexes can be delivered to cells and this process can be 
facilitated using cationic amphiphiles. Representative uses 
of the therapeutic compositions containing lipid, oligonucle 
otides and cationic amphiphiles are as folloWs: gene therapy, 
anticancer therapy, diseases involving in?ammation and 
infectious diseases. The oligonucleotide therapeutics are 
provided in the form of a plasmid in combination With 
camptothecin drugs, and cationic amphiphiles capable of 
interacting With both the lipid, oligonucleotide and 
oligonucleotide-camptothecin drug complex. 
Certain amphiphiles and neutral molecules as Well can 
covalently associate With macromolecules. An important 
example of these types of agents are photosensitiZers. These 
agents are exempli?ed by prophyrin-based photosensitiZers, 
including prophyrins, chlorins, bacteriochlorins, polypyr 
rolic macrocycles phthalocyanines. The photosensitiZers, 
especially prophyrins can conjugate biomolecules, including 
biological active molecules such as steroids, lipids, peptides, 
nucleosides, nucleotides, antibody conjugates, steroid 
conjugates, sugar conjugates, and mono and polynucleotide 
conjugates. Peptides along With other compounds such as 
membrane transport molecules and DNA ligands can also be 
conjugated. The photosensitiZers can be activated by light in 
order to covalently bind the agent to DNA. The camptoth 
ecins can be photoactivated and complexed to DNA as Well 
(Leteurtre et al., 1993). This invention claims 
oligonucleotide-camptothecin complexes and 
oligonucleotide-camptothecin drug in combination With 
other drugs Where the agents have been covalently attached 
using light. Such covalently modi?ed aggregates may 
exhibit improvements in terms of stabiliZing and delivering 
the active agents to the tumor. Such covalently attached 
molecules useful for the desired purposes undergo disas 
sembly upon reaching the tumor site thereby releasing active 
agent. 
Polyamines can be used as carriers for oligonucleotide 
camptothecin drug complexes. Polyamines are ubiquitous 
cell components, and these agents are essential for normal 
groWth. Polyamine analogues, notably those With ethyl or 
benZyl groups on the terminal nitrogen atoms, have potent 
antiproliferative activity and are promising agents for the 
treatment of cancer. The association of cad onic polyamines 
With negatively-charged oligonucleotides induces signi? 
cant structural changes in the macromolecules in cell-free 
systems. Spermine and spermidine can cause DNA to con 
dense and aggregate and induce transition as in B-to-Z in 
certain DNA sequences. Because it is the binding of camp 
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tothecin lactone forms to DNA that result in stabiliZation of 
the active forms of the drug, oligonucleotide-camptothecin 
drug-polyamines and oligonucleotide-camptothecin drug 
polyamine-lipid complexes should exhibit favorable in?u 
ences on the drugs by acting to conserve the active lactone 
forms. 
Cyclodextrins 
Cyclodextrins can be used as cellular delivery systems for 
oligonucleotide-camptothecin-drug complexes. Oligonucle 
otides can bind noncovalently With substituted and non 
substituted beta gamma cyclodextrin and derivatives. The 
uptake of oligonucleotides into cells can be modulated With 
cyclodextrin. The pharmaceutical formulation of 
oligonucleotide-camptothecin drug complex With cyclodex 
trin and oligonucleotide-camptothecin-lipid complex can 
render a physiologically acceptable carrier. The inclusion of 
cyclodextrins in camptothecin-lipid complexes can impact 
on biological activities by increasing the cellular uptake and 
accumulation of both the active lactone form of camptoth 
ecin drug and of the exogenous oligonucleotide included in 
the formulation. The formulations can be of potential utility 
in diseases such as cancer, infectious diseases such as in the 
case of viral infections, and in?ammation. Formulation of 
oligonucleotide-camptothecin drug complexes and 
camptothecin-lipid-oligonucleotide complexes With cyclo 
dextrins may be useful in increasing the solubility and 
stability of an oligonucleotide-camptothecin drug complex 
in vitro and in vivo. 
Camptothecin Drugs 
Preferably, the camptothecin drugs utiliZed in this inven 
tion are any of the knoWn camptothecin drugs found in the 
prior art to have the necessary liposomal loading, loW 
toxicity and high antitumor activity for the intended pur 
pose. Examples of the camptothecin drugs that may be 
utiliZed include: 
A) Wherein R is N02, NH2, N3 hydrogen, 
trimethylsilylmethylaminomethyl, halogen (F, Cl, Br, 
I)>COOH, OH, O—C1_3 alkyl, SH, S—C1_3 alkyl CN, 
CH2 NH2, NH—C1_3 alkyl CH2—NH—C1_3 alkyl, 
N(C1_3 alkyl)2, OCH2CH2N(CH2CH2OH)2, 
NHCH2CH2N(CH2CH2OH), and SCHZCHZN 
(CH2CH2OH)2, OCH2CH2CH2N(CH2CH2OH)2, 
NHCH2CH2CH2N(CH2CH2OH)2 and SCHZCHZCHZN 
(CH2CH2OH)2, OCH2CH2N(CH2CH2CH2OH)2, 
NHCH2CH2N(CH2CH2CH2OH)2 and SCHZCHZN 
(CH2CH2CH2OH)2, 
OCH2CH2CH2N(CH2CH2CH2OH)2, NHCH2CH2CH2N 
(CHZCHZCHZOH)2 and SCHZCHZCHZN 
(CHZCHZCHZOH), OCH2CH2N(C1_3 alkyl)2, 
NHCH2CH2N(C1_3 alkyl)2 and SCH2CH2N(C1_3 alkyl)2, 
OCH2CH2CH2N(C1_3 alkyl)2, NHCH2CH2CH2N(C1_3 
alkyl)2- and SCH2CH2CH2N(C1_3alkyl)2, CHO or C1_3 
alkyl and Z is H, C1_8 alkyl, trimethylsilyl, 
tertbutyldimethylsilyl, trimethylsilylmethyl, trimethylsi 
lymethylaminomethyl t-butyldimethylsilylethyl, 
trimethylsilylethyl, 
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or CH2NR1R2 Where (a) R1 and R2 are, independently, 
hydrogen, C1_6 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl-C2_ 
6, alkenyl, hydroXy-C1_6 alkyl CL6 alkoXy CL6 alkyl 
5,6,7-membered heterocyclic rings contains one or more 
O, N, S (b)R1 is hydrogen, CL6 alkyl, C3_7 cycloalkyl, 
C3_7 cycloall<yl-C1_6 alkyl, C2_6 alkenyl, hydroXy-C1_6 
alkyl or C1_6 alkoXy-C1_6 alkyl and R2 is —COR3 Where 
R3 is hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, C3_7 
cycloalkyl-C3_7 cycloall<yl-C1_6 alkyl, C2_6 alkenyl, 
hydroXy-C1_6 alkyl, CL6 alkoXy, CL6 alkoXy-C1_6alkyl, or 
(c) R1 and R2 taken together With the nitrogen atom to 
Which they are attached form a saturated 3—7 membered 
heterocyclic ring Which may contain a O, S or NR4 group, 
Where R4 is hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, aryl, 
aryl substituted With one or more groups selected from the 
group consisting of C1_6 alkyl, halogen nitro amino, CL6 
alkylamino, perhalo-C1_6 alkyl, hydro-CL6 alkyl, CL6 
alkoXy, CL6 alkoXy-C1_6alkyl and —COR5 Where R5 is 
hydrogen, C1_6 alkyl, perhalo-C1_6 alkyl, C1_6 alkoXy, aryl 
and aryl substituted With one or more C1_6alkyl, perhalo 
CL6 alkyl, hydroXy-C1_6alkyl, or CL6 alkoXy-C1_4 alkyl 
groups. In the structure shoWn above, n is an integer of 1 
or 2. Preferred aryl groups are phenyl and naphthyl; 
B) Wherein R6 is hydrogen, cyano, formyl, hydroXy, CL8 
alkoXy, nitro, amino, halogen (I Br, Cl, F), C1_8 alkyl, 
tri?uoromethyl, trimethylsilylmethylamino, 
aminomethyl, aZido, amido, hydraZino, 
—OC(O)R7 or OC(O)—NR7R8, Where R7 and R8 are, 
independently hydrogen or C1_8 alkyl; and Z is H, CL8 
alkyl, trimethylsilyl, tertbutyldimethylsilyl, 
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trimethylsilylmethyl, 
trimethylsilylmethylaminomethyl, 
t-butyldimethylsilylethyl, trimethylsilylethyl, 
or CHZNRJLR2 Where (a) R1 and R2 are, independently, 
hydrogen, C1_6 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl 
C2_6 alkenyl, hydroXy-C1_6alkoXy, CL6 alkoXy C1_6-alkyl, 
5,6,7-membered heterocyclic rings contains one or more 
O, N, S (b)R1 is hydrogen, CL6 alkyl, C3_7 cycloalkyl, 
C3_7cycloalkyl-C1_6 alkyl, C2_6 alkenyl, hydroXy-C1_6 
alkyl or CL6 alkoXy-C1_6 alkyl and R2 is —COR3 Where 
R3 is hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, C3_7 
cycloalkyl, C3_7 cycloalkyl-C1_6 alkyl, C2_6 alkenyl, 
hydroXy-C1_6 alkyl, C1_6 alkoXy, C1_6 alkoXy-C, alkyl, or 
(c) R1 and R2 taken together With the nitrogen atom to 
Which they are attached form a saturated 3—7 membered 
heterocyclic ring Which may contain a O, S or NR4 group, 
Where R4 is hydrogen, C1_6 alkyl, perhalo-C1_6 alkyl, aryl, 
aryl substituted With one or more groups selected from the 
group consisting of CL6 alkyl, halogen, nitro, amino, CL6 
alkylamino, perhalo-C1_6 alkyl, hydroXy-C1_6 alkyl, CL6 
alkoXy, C1_6 alkoXy-C1_6 alkyl and —COR5 Where R1 is 
hydrogen, CL6 alkyl, perhalo-C1_6 alkyl, CL6 alkoXy, 
aryl, and aryl substituted With one or more CL6 alkyl, 
perhalo-C1_6 alkyl, hydroXy-C1_6alkyl, or C1_6 alkoXy 
CL6 alkyl groups. In the structure shoWn above, n is an 
integer of 1 or 2. Preferred aryl groups are phenyl and 
naphthyl; 
C. Additional camptothecin compounds of the present 
invention have the hydroXyl group at the 20-position 
esteri?ed With:—Aromatic and aliphatic carboXylic acids, 
aliphatic carboXylic acid With the formula —O(CO)— 
(CH2)m—CH3, Where m=1—20, and polyethers; O-PEG 
OH (MW=350—5000), O-PEG-OMe (MW=350—5000), - 
alpha-carboXyl group of a naturally occurring amino acid 
to form a group of the formula —OC(O)—CH2)m— 
NRloRll, Where m=1—6 or —OC(O)CHR9NR1OR11, 
Where R9 is the side chain of one of the naturally 
occurring ot-amino acids, R10 and R11 are, independently, 
hydrogen or C1_8, alkyl. Suitable side chains R9 are the 
side chains of the amino acids glycine, alanine, valine, 
leucine, isoleucine, phenylalanine tryptophan, lysine, 
arginine, histidine, aspartate, glutamate, asparagine, 
glutamine, cysteine and methionine. Particularly pre 
ferred esters are glycinate esters. These esters are pro 
drugs Which are converted to the camptothecin compound 
by hydrolysis of the ester bond; 







